Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients

Drug Design, Development and Therapy

Volumn 6, Issue , 2012, Pages 289-295

  Doesch, Andreas O ^a   Repp, Janika ^a   Hofmann, Nina ^a   Erbel, Christian ^a   Frankenstein, Lutz ^a   Gleissner, Christian A ^a   Schmidt, Constanze ^a   Ruhparwar, Arjang ^a   Zugck, Christian ^a   Schnitzler, Paul ^a   Ehlermann, Philipp ^a   Dengler, Thomas J ^b   Katus, Hugo A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SLK Kliniken Heilbronn   (Germany)

Author keywords

Cytomegalovirus infection; Heart transplantation; Valganciclovir prophylaxis

Indexed keywords

CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIGEN PP65; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CHEMOPROPHYLAXIS; COLITIS; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; VIRUS PNEUMONIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84872357778     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S36578     Document Type: Article

References (22)

1. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:928-936.
2. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation: fnal report. Am J Transplant. 2005;5: 218-227.
3. Paya C V, Razonable RR. Cytomegalovirus infection after organ transplantation. In: Transplant Infections. 2nd ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2003.
4. Rubin RH. Cytomegalovirus infection in the organ transplant recipient: The end of the "silo hypothesis". Curr Opin Infect Dis. 2007;20: 399-407.
5. Kranz B, Vester U, Wingen AM, et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant. 2008;12:474-478.
6. Hjelmesaeth J, Muller F, Jenssen T, Rollag H, Sagedal S, Hartmann A. Is there a link between cytomegalovirus infection and new-onset post transplantation diabetes mellitus? Potential mechanisms of virus induced beta-cell damage. Nephrol Dial Transplant. 2005;20:2311-2315.
7. [No authors listed]. Cytomegalovirus. Am J Transplant. 2004;4 Suppl 10: 51-58.
8. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid- organ transplants: a systematic review of randomised controlled trials. Lancet. 2005;365:2105-2115.
9. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Metaanalysis: the effcacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005;143:870-880.
10. Lowance D, Neumayer HH, Legendre CM, et al; International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med. 1999;340:1462-1470.
11. Doyle AM, Warburton KM, Goral S, Blumberg E, Grossman RA, Bloom RD. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation. 2006;81:1106-1111.
12. Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant. 2004;4: 1635-1642.
13. Valentine VG, Weill D, Gupta MR, et al. Ganciclovir for cytomegalovirus: a call for indefnite prophylaxis. J Heart Lung Tranplant. 2008 Aug; 27(8);875-81.
14. Schnitzler MA, Lowell JA, Hmiel S P, et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of HLA-DR matching. J Am Soc Nephrol. 2003;14: 780-785.
15. Delgado JF, Manito N, Almenar L, et al. Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study. Transpl Infect Dis. 2011;13:136-144.
16. Limaye A P, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000;356:645-649.
17. Landry ML, Ferguson D. Comparison of quantitative cytomegalovirus antigenemia assay with culture methods and correlation with clinical disease. J Clin Microbiol. 1993;31:2851-2856.
18. Wagner HJ, Fischer L, Jabs WJ, Holbe M, Pethig K, Bucsky P. Longitudinal analysis of Epstein-Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction. Transplantation. 2002;74:656-664.
19. Koch A, Daniel V, Dengler TJ, Schnabel PA, Hagl S, Sack FU. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat). J Heart Lung Transplant. 2005;24:708-713.
20. Hodson EM, Craig JC, Strippoli GF, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2008;2:CD003774.
21. Humar A, Lebranchu Y, Vincenti F, et al. The effcacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10:1228-1237.
22. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89:779-795.